Application
MAP3K7IP3 Antibody (N-term) western blot analysis in HL-60 cell line lysates (35ug/lane).This demonstrates the MAP3K7IP3 antibody detected the MAP3K7IP3 protein (arrow).| Product Name | MAP3K7IP3 Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | TAB3; MAP3K7IP3; TGF-beta-activated kinase 1 and MAP3K7-binding protein 3; Mitogen-activated protein kinase kinase kinase 7-interacting protein 3; NF-kappa-B-activating protein 1; TAK1-binding protein 3; TGF-beta-activated kinase 1-binding protein 3 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | MAP3K7IP3 |
|---|---|
| Alternative Names | TAB3 MAP3K7IP3 TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 Mitogen-activated protein kinase kinase kinase 7-interacting protein 3 NF-kappa-B-activating protein 1 TAK1-binding protein 3 TGF-beta-activated kinase 1-binding protein 3 |
| Molecular Weight(MW) | 78683 Da |
| Function | Adapter linking MAP3K7/TAK1 and TRAF6 or TRAF2. Mediator of MAP3K7 activation, respectively in the IL1 and TNF signaling pathways. Plays a role in activation of NF-kappa-B and AP1 transcription factor. Isoform 2 may be an oncogenic factor |
| Tissue Specificity | Widely expressed. Constitutively overexpressed in certain tumor tissues. Isoform 1 is a major transcript while isoform 2 is a minor transcript |
| Entrez Gene | 257397 |
|---|---|
| Nucleotide Accession | NP_690000.2 |
Application
MAP3K7IP3 Antibody (N-term) western blot analysis in HL-60 cell line lysates (35ug/lane).This demonstrates the MAP3K7IP3 antibody detected the MAP3K7IP3 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
